These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 7923128)
1. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid. Sung C; Blaney SM; Cole DE; Balis FM; Dedrick RL Cancer Res; 1994 Oct; 54(19):5118-22. PubMed ID: 7923128 [TBL] [Abstract][Full Text] [Related]
2. Plasma and cerebrospinal fluid pharmacokinetic study of topotecan in nonhuman primates. Blaney SM; Cole DE; Balis FM; Godwin K; Poplack DG Cancer Res; 1993 Feb; 53(4):725-7. PubMed ID: 8428353 [TBL] [Abstract][Full Text] [Related]
3. Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly. Haas NB; LaCreta FP; Walczak J; Hudes GR; Brennan JM; Ozols RF; O'Dwyer PJ Cancer Res; 1994 Mar; 54(5):1220-6. PubMed ID: 8118810 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Grochow LB; Rowinsky EK; Johnson R; Ludeman S; Kaufmann SH; McCabe FL; Smith BR; Hurowitz L; DeLisa A; Donehower RC Drug Metab Dispos; 1992; 20(5):706-13. PubMed ID: 1358575 [TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. Baker SD; Heideman RL; Crom WR; Kuttesch JF; Gajjar A; Stewart CF Cancer Chemother Pharmacol; 1996; 37(3):195-202. PubMed ID: 8529278 [TBL] [Abstract][Full Text] [Related]
6. Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates. Thompson PA; Berg SL; Aleksic A; Kerr JZ; McGuffey L; Dauser R; Nuchtern JG; Hausheer F; Blaney SM Cancer Chemother Pharmacol; 2004 Jun; 53(6):527-32. PubMed ID: 14997342 [TBL] [Abstract][Full Text] [Related]
7. [Pharmacokinetics of SK & F 104864 in experimental animals. I. Plasma level]. Fujita H; Okamoto M; Takao A; Abe H; Ishii R; Takeda K Gan To Kagaku Ryoho; 1995 Oct; 22(12):1783-7. PubMed ID: 7574810 [TBL] [Abstract][Full Text] [Related]
8. Topotecan lacks third space sequestration. Gelderblom H; Loos WJ; Verweij J; de Jonge MJ; Sparreboom A Clin Cancer Res; 2000 Apr; 6(4):1288-92. PubMed ID: 10778953 [TBL] [Abstract][Full Text] [Related]
9. Limited sampling model for area under the concentration time curve of total topotecan. Minami H; Beijnen JH; Verweij J; Ratain MJ Clin Cancer Res; 1996 Jan; 2(1):43-6. PubMed ID: 9816088 [TBL] [Abstract][Full Text] [Related]
10. Intrathecal administration of topotecan in nonhuman primates. Blaney SM; Cole DE; Godwin K; Sung C; Poplack DG; Balis FM Cancer Chemother Pharmacol; 1995; 36(2):121-4. PubMed ID: 7767947 [TBL] [Abstract][Full Text] [Related]
11. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. Jacobs SS; Fox E; Dennie C; Morgan LB; McCully CL; Balis FM Clin Cancer Res; 2005 Feb; 11(4):1669-74. PubMed ID: 15746072 [TBL] [Abstract][Full Text] [Related]
12. Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. Abbruzzese JL; Madden T; Sugarman SM; Ellis AL; Loughlin S; Hess KR; Newman RA; Zwelling LA; Raber MN Clin Cancer Res; 1996 Sep; 2(9):1489-97. PubMed ID: 9816325 [TBL] [Abstract][Full Text] [Related]
14. A four-hour topotecan infusion achieves cytotoxic exposure throughout the neuraxis in the nonhuman primate model: implications for treatment of children with metastatic medulloblastoma. Zamboni WC; Gajjar AJ; Mandrell TD; Einhaus SL; Danks MK; Rogers WP; Heideman RL; Houghton PJ; Stewart CF Clin Cancer Res; 1998 Oct; 4(10):2537-44. PubMed ID: 9796988 [TBL] [Abstract][Full Text] [Related]
15. Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion. Blaney SM; Balis FM; Cole DE; Craig C; Reid JM; Ames MM; Krailo M; Reaman G; Hammond D; Poplack DG Cancer Res; 1993 Mar; 53(5):1032-6. PubMed ID: 8439950 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of tiazofurin in the plasma and cerebrospinal fluid of rhesus monkeys. Grygiel JJ; Balis FM; Collins JM; Lester CM; Poplack DG Cancer Res; 1985 May; 45(5):2037-9. PubMed ID: 3986760 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. van Warmerdam LJ; Verweij J; Schellens JH; Rosing H; Davies BE; de Boer-Dennert M; Maes RA; Beijnen JH Cancer Chemother Pharmacol; 1995; 35(3):237-45. PubMed ID: 7805183 [TBL] [Abstract][Full Text] [Related]
18. Topotecan vitreous levels after periocular or intravenous delivery in rabbits: an alternative for retinoblastoma chemotherapy. Carcaboso AM; Bramuglia GF; Chantada GL; Fandiño AC; Chiappetta DA; de Davila MT; Rubio MC; Abramson DH Invest Ophthalmol Vis Sci; 2007 Aug; 48(8):3761-7. PubMed ID: 17652749 [TBL] [Abstract][Full Text] [Related]
19. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364 [TBL] [Abstract][Full Text] [Related]
20. Plasma and cerebrospinal fluid pharmacokinetics of 9-aminocamptothecin (9-AC), irinotecan (CPT-11), and SN-38 in nonhuman primates. Blaney SM; Takimoto C; Murry DJ; Kuttesch N; McCully C; Cole DE; Godwin K; Balis FM Cancer Chemother Pharmacol; 1998; 41(6):464-8. PubMed ID: 9554590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]